New Data Position Lazertinib As Strong Contender In 1L NSCLC

Potential Tagrisso Challenger?

Yuhan’s oncology drug lazertinib is set to expand its indications in Korea to the first-line treatment of EGFR mutation-positive advanced NSCLC, based on new top-line Phase III data showing clinical benefits for all patient sub-groups.

lung cancer
New Indication Filing for Lazertinib Expected In Korea in Q1 '23 • Source: Shutterstock

South Korea's Yuhan Corporation has unveiled promising top-line Phase III data for its novel cancer drug lazertinib in the first-line treatment of epidermal growth factor receptor (EGFR) mutation-positive, advanced non-small cell lung cancer (NSCLC), concluding the drug will be competitive as a monotherapy and raising hopes for a second standard-of-care option for a form of the malignancy seen more frequently in Asia.

The top-line findings from the LASER301 study, presented at the ESMO (European Society for Medical Oncology) Asia Congress held in...

Welcome to Scrip

Create an account to read this article

More from Clinical Trials

Sanofi/Orano Look To Next Steps After Phase II Radiotherapy Success

 

The companies announced positive Phase II results for AlphaMedix, a lead 212-based alpha emitter therapy for gastroenteropancreatic neuroendocrine tumors.

Psoriasis Submissions Iin The Bag, J&J Advances Icotrokinra Into Phase III For Ulcerative Colitis

 
• By 

The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.

Hope Medicine Ready To Bring Potential First-in-Class Endometriosis Treatment Into Phase III

 

The non-hormonal drug could be a big step forward in treating pain associated with the condition, but the Chinese company may still need a partner for its Phase III studies and eventual commercialization.

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By 

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

More from R&D

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By 

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Ribomic Positions Itself As Latest Potential Achondroplasia Competitor

 

The company announced positive Phase II data for umedaptanib pegol and plans to move it into Phase III development in fiscal year 2026.

Peter Marks Brings Genetic Medicines Street Cred To Lilly

 

FDA’s former CBER director is joining industry as senior VP of molecule discovery and head, infectious disease at Eli Lilly.